Eli Lilly's Weight Loss Pill Remains a Serious Competitor for Novo's Oral Wegovy Despite Disappointing Data

After the release of disappointing study data, Eli Lilly's stock is slowly recovering. The new weight loss pill Orforglipron from Eli Lilly showed lower weight loss and stronger side effects than expected, which brings its effectiveness slightly below that of Novo Nordisk's (i) oral Semaglutide. Market potential despite a setback Despite the weaker data, analysts see Eli Lilly's pill as a strong competitor. The market for weight loss medications is lucrative and demands more practical options than the currently dominant weekly injections....